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Tackling dipeptidyl peptidase IV in neurological 
disorders
Introduction
Dipeptidyl peptidase-IV (DPP-IV) (aka adenosine deaminase 
complexing protein 2 or T-cell activation antigen CD26) is a 
serine exopeptidase widely expressed throughout the body. 
DPP-IV is usually found tethered to the intravascular portion 
of vascular endothelial cells (where it is less active) but also 
exists in a soluble fully active circulating form (Mentlein et 
al., 1993; Mentlein, 1999; Omar and Ahrén, 2014). It belongs 
to the S9B protein family that acts on the N-terminus of the 
X-proline dipeptides, including chemokines, neuropeptides, 
and peptide hormones. Beside the intravascular compartment, 
DPP-IV is expressed on the surface of several types of cells in 
the form of a type II transmembrane glycoprotein. 
One of the main known functions of the DPP-IV is to 
deactivate incretins. The enzyme is strongly implicated in 
the inhibition of the biological activity of glucose-regulating 
hormones, such as glucagon-like peptide-1 (GLP-1), pituitary 
adenylate cyclase-activating polypeptide (PACAP) and glu-
cose-dependent insulinotropic polypeptide (GIP) (Zhu et al., 
2003; Matteucci and Giampietro, 2009; Marzagalli et al., 2015). 
DPP-IV is also broadly distributed in numerous organs/tissues 
such as the liver, lungs, intestinal epithelium, placenta, kidney, 
renal proximal tubules and neurons, as well as in bodily fluids 
such as in seminal and synovial fluids, urine, plasma and the 
cerebrospinal fluid (Green et al., 2006a; Kosaraju et al., 2013a). 
Aside from its canonical role in glucose metabolism, DPP-IV 
is also largely involved in regulating various non-incretin re-
lated processes in the body, including inflammatory responses, 
neurophysiological and neuroendocrine functions (Aertgeerts 
et al., 2004). DPP-IV, through its enzymatic activity, causes 
the degradation of several cytokines, chemokines and neu-
ropeptides regulating inflammation, immunity, and vascular 
function that are normally released in the blood stream (Fadini 
and Avogaro, 2011). In addition, DPP-IV is thought to take 
part in the control of the maturation and phenotypic differ-
entiation of T-lymphocytes, since activated T-cells are DPP-
IV+, making it a particularly attractive target for studies on 
immune system reactivity. 
From a biochemical point of view, DPP-IV cleavage of sub-
strates occurs at the N-terminus of X-proline dipeptides. An 
example of such cleavage is that observed with GLP-1. DPP-IV 
enzymatically cleaves GLP-1 at the amino acid ‘Alanine’ locat-
ed in the second position, converting the intact GLP-1 (7–36) 
amide peptide into the GLP-1 (9–36) amide fragment (missing 
the first two amino acids), which is then biologically inactive 
(as depicted in Figure 1). Inactivation of GLP-1 by DPP-IV 
is rapid and extensive; for this reason DPP-IV inhibition has 
been estimated to significantly increase GLP-1 bioavailability 
and concentration, especially in the peripheral venous plasma 
and in portal blood (Hjøllund et al., 2011; Nagatsu, 2017). In-
terestingly, DPP-IV-mediated enzymatic inactivation has been 
described for at least two further relevant circulating bioactive 
peptides involved in glucose metabolisms, among other func-
tions: PACAP and GIP. 
As illustrated by Green and co-workers, inactivation of 
circulating PACAP by DPP-IV occurs rapidly (Green et al., 
2006b). Combined genetic and tandem mass spectrometry 
studies have demonstrated that the levels of PACAP clearance 
is significantly lower in mice deficient for the DPP-IV gene, 
due to abolished enzymatic activity at the N-terminal portion 
of the peptide (Zhu et al., 2003; Ma et al., 2015). In support of 
these findings, a research group has shown that the adminis-
tration of DPP-IV inhibitors in mice improved the insulino-
tropic effects of PACAP and improved their long-term glycae-
mic profile (Ahrén and Hughes, 2005). Taken together, these 
findings suggest that the effects of DPP-IV inhibitors extend 
circulating PACAP half-life, hence its peripheral and central 
nervous system (CNS) bioavailability (Yada et al., 2000; Ahrén 
and Hughes, 2005; Omar and Ahrén, 2014). 
Glucose-dependent insulinotropic polypeptide (GIP) is an-
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other incretin molecule functionally inactivated by the endog-
enous DPP-IV. Interestingly, studies addressing the function 
of DPP-IV inhibitors have demonstrated that GIP levels are 
increased much more than GLP-1 levels following inhibitor 
treatment, suggesting that GIP might be a preferential target 
of DPP-IV compared to GLP-1 and PACAP (Yabe et al., 2017; 
Yanagimachi et al., 2017).
DPP-IV Inhibition – Overview of the Direct 
and Indirect Effects
In this section, we will attempt to summarise the modes of ac-
tion through which DPP-IV inhibitors elicit anti-inflammatory 
and neuroprotective functions, with specific emphasis on the 
benefits arising from their use in the treatment of chronic con-
ditions such as diabetes mellitus. Of note, the indirect effects 
triggered by DPP-IV inhibition emerge as the predominant 
therapeutic mechanisms observed with respect to the CNS. 
Direct effects
The positive effects of DPP-IV inhibition are believed to cor-
relate, at least in part, with its direct modulatory activities on 
those molecular pathways driving the inflammatory response, 
generally defined as ‘the inflammasome’. In animal models of 
diabetes, there is evidence showing that treatment with DPP-
IV inhibitors cause a reduction in retinopathy, with a decrease 
in the local release pro-inflammatory cytokines and lower 
interleukin-1β immunoreactivity, particularly in the gangli-
on cell layer and inner plexiform layer of the retina (Zhang 
et al., 2011). In clinical studies, DPP-IV inhibitors have been 
reported to diminish retinal thinning, lower the ratio of an-
ti-inflammatory/pro-inflammatory cytokines and the apop-
totic cascade in diabetic patients. These properties of DPP-IV 
inhibition have been corroborated by pre-clinical evidence in 
type 1 diabetic rats, where enzyme inhibition also prevented 
blood-retinal barrier breakdown, increased the survival rates of 
retinal neurons and reduced the overall inflammatory burden 
(Gonçalves et al., 2014). Sitagliptin, a FDA approved oral anti-
hyperglycemic drug of the DPP-IV inhibitor class, has shown 
to reduce proliferative micro-angiopathy in the diabetic retina 
Figure 1 Amino acid structure of glucagon-like peptide-1 (GLP-1)
and dipeptidyl peptidase IV (DPP-IV) cleavage site.
by preventing the increase of ICAM-1 protein (intercellular 
adhesion molecule-1, an endothelial adhesion molecule com-
monly induced in diabetes) and by reducing the expression of 
the pro-apoptotic BAX gene when intravitreally injected (Zhang 
et al., 2011). Additional studies investigating the role of DPP-
IV inhibition in the context of immune regulation have strong-
ly supported its anti-inflammatory function. Shirakawa and 
colleagues reported that DPP-IV inhibitors modulate immune 
cells activation in the adipose tissue (Shirakawa et al., 2011), 
while others suggested that blockade of DPP-IV activity may 
significantly reduce the expression of the macrophage marker 
F4/80 and their activation (Klein et al., 2014). These results 
confirm that blockade of DPP-IV may have direct immuno-
suppressive effects, providing interesting insights for the future 
therapeutic development of treatments neurological conditions 
with recognizable immune-related dysfunctions. 
Indirect effects
GLP-1 and GLP-2 are two main targets of DPP-IV. Both 
molecules are abundant in the brain, along with their re-
lated receptors GLP-1R and GLP-2R (Lovshin et al., 2001). 
Upon inhibition of DPP-IV, GLP-1 and -2 are spared from 
enzymatic cleavage and therefore can exert their biological 
functions. Active GLP-1 and GLP-2, bind to the G-protein 
coupled receptor GLP-1R to increase intracellular cyclic ad-
enosine monophosphate (cAMP). This leads to activation of 
protein kinase A (PKA), which phosphorylates and activates 
the PI3K-Akt and MAPK pathways, two downstream signal-
ling cascades involved in promoting protein synthesis, axonal 
growth, mitochondrial function, inhibition of apoptosis and 
attenuation of the neuroinflammatory response (Baggio and 
Drucker, 2007; Flock et al., 2007). To date, GLP-1 neuro-
trophic and anti-apoptotic activities have been demonstrated 
in different neuronal cell lineages. GLP-1 facilitates differenti-
ation and induces neurite outgrowth in PC12 neuronal cells, 
and protects rat hippocampal neurons from apoptosis (Bru-
baker and Drucker, 2004). These findings have led to the idea 
that GLP-1 might be useful for the treatment of Alzheimer’s 
and other neurodegenerative diseases (Brubaker and Drucker, 
2004; Li et al., 2010). In line with GLP-1 studies, researchers 
have found that GLP-2, (another target of DPP-IV), is also 
capable to protect the CNS from excitotoxic insults. GLP-2 
stimulates the proliferation of rat astrocytes in vitro (Velázquez 
et al., 2003) and reduces the extent of glutamate-induced cy-
totoxicity in cultured murine hippocampal cells (Lovshin et 
al., 2004), supporting an additional role of the DPP-IV inhibi-
tion in boosting GLP-2 protective activity. 
In mice deficient for the GLP-1R, a study has demonstrat-
ed that these animals exhibit learning deficits and enhanced 
susceptibility to neural injury following kainate administra-
tion (During et al., 2003). GLP-1R agonist administration to 
wild-type but not to knockout animals prevented kainate-in-
duced apoptosis, suggesting that direct targeting of GLP-1R 
or the use of drugs aimed at extending GLP-1 half-life could 
indeed be effective for the treatment of neurodegenerative 
diseases (During et al., 2003; Bae, 2016). 
Further, some evidences propose that the effects of DPP-
IV inhibition on the GLP-1/GLP-1R signalling cascade 
could also be beneficial in improving late complications of 
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diabetes in animal models, including peripheral neuropathy 
(Jin et al., 2009). In uncontrolled diabetic patients, DPP-IV 
inhibition by sitagliptin reduced the levels of C-reactive pro-
teins in the blood of diabetic patients, and significantly in-
creased the amount of circulating CD34+ cells (i.e., a marker 
of endothelial progenitor cells), suggesting an additional 
ameliorative role in the vascular compartment (Matsubara 
et al., 2013; Nakamura et al., 2014). 
DPP-IV Inhibition in Neurological Disorders
Since the discovery of neurotrophic and immune regulat-
ing functions of DPP-IV inhibitors in the CNS, more and 
more interest has been given to this class of drugs for the 
management of neuroinflammatory/neurodegenerative 
disorders; evidence from basic and pre-clinical research has 
now demonstrated that this has become more than just a 
forthright association. Below we will discuss current experi-
mental evidences in support of the use of DPP-IV inhibitors 
in the context of the major chronic progressive neurodegen-
erative conditions where overt signs of neuroinflammation 
have been reported, such as Parkinson’s disease (PD), Alz-
heimer’s disease (AD) and multiple sclerosis (MS). 
DPP-IV inhibition in PD 
PD is a multifactorial neurodegenerative disease considered 
to be the result of both environmental and genetic factors 
(Trinh and Farrer, 2013). Despite the efforts, to date the 
exact pathogenesis of PD is not completely understood. The 
main pathological features of PD are the massive cell loss of 
dopaminergic neurons in the substantia nigra pars compacta 
(SnPc) (Davie, 2008) and the presence of Lewy bodies (accu-
mulations of the protein alpha-synuclein) in the surround-
ing neurons. By the time neuronal loss becomes obvious, as-
trocytes’ death and signs of chronic microgliosis are already 
established (Kim et al., 2013), suggesting that inflammation 
might precede or even initiate the condition.
Molecular genetics and cell biology have identified links 
between PD and type 2 diabetes mellitus (T2DM). A num-
ber of discoveries have highlighted the existence of common 
cellular pathways that correlate neurodegenerative processes 
with abnormal mitochondrial function and abnormal glu-
cose metabolism. In this context, the relationship between 
DPP-IV inhibitors and PD has proven to be mostly indirect, 
but has significantly contributed to provide the scientific 
bases for the discovery of a new synthetic analogues of GLP-
1. One such analogue, known as exenatide, exhibits potent 
GLP-1R agonist activities, and available data seems to point 
to both its robust anti-inflammatory functions (Huang et al., 
2012; Gullo et al., 2017) and its role in stimulating neuro-
genesis (Hunter and Hölscher, 2012; Gumuslu et al., 2016). 
Moreover, a very recent clinical trial testing exenatide in PD 
patients has proven to be promising, with significant im-
provements in motor scores, which were sustained beyond 
the period of drug exposure (Athauda et al., 2017). 
A growing number of studies show that GLP-1 mimetics 
can act as a neurotrophic factors (Perry et al., 2002), en-
hance mitochondrial biogenesis (An et al., 2015), inhibit 
apoptosis (Li et al., 2016), reduce the inflammatory response 
and oxidative stress (Jalewa et al., 2016), all elements that 
have contributed to establish the beneficial properties of 
GLP-1 agonists across a range of experimental models of PD 
(Athauda and Foltynie, 2016). In fact, due to the number of 
cellular processes GLP-1R modulates, it is perhaps not un-
surprising that GLP-1 stimulation can rescue functions that 
become disrupted in PD (Baggio and Drucker, 2007). 
Recently, a population-based case control study found a 
significantly reduced incidence of PD among individuals 
with a record of DPP-IV use. Svenningsson and colleagues 
conducted a nationwide case-control study in a Swedish 
cohort receiving DPP-IV inhibitors-based therapy. The 
authors suggested the beneficial effects might not only be a 
consequence of the increase in GLP-1 → GLP-1R interac-
tion, but also to the positive contribution provided by other 
enzymatic substrates spared from DPP-IV cleavage, such as 
PACAP, substance P, neuropeptide Y and gastrin-releasing 
peptide (Matteucci and Giampietro, 2015), as well as their 
inhibitory activities on T cells proliferation and cytokine re-
lease (Yazbeck et al., 2009; Svenningsson et al., 2016). 
In a rotenone environmental model of PD, rats receiving 
pre-treatment with a DPP-IV inhibitor (vildagliptin) for a 
week exhibited resilience to dopaminergic cell loss in the 
SnPc and striatal terminals and increased dopamine syn-
thesis compared to the untreated controls (Abdelsalam and 
Safar, 2015). Interestingly, similar results were described 
by Nassar and co-workers using another DPP-IV inhibitor 
(saxagliptin) (Nassar et al., 2015). These authors also found 
that saxagliptin treatment decreased the rotenone-induced 
nuclear factor-κΒ, inducible nitric oxide synthase, tumor ne-
crosis factor-α, ICAM-1 and myeloperoxidase levels, all sig-
natures of ongoing inflammation. The antiapoptotic marker 
B-cell lymphoma-2 and brain derived neurotrophic factor 
levels were both enhanced by saxagliptin and reductions in 
caspase-3 and its intrinsic apoptotic activator cytochrome 
C were also observed (Nassar et al., 2015). In conclusion, 
there is ample data to support the idea that DPP-IV inhibi-
tors and GLP-1 mimetics might exert beneficial roles in PD 
(summarized in Table 1), although more insights on the 
specific modes of action and targeted substrates are needed 
to address the safety profile of these drugs in PD and/or for 
the identification of unwanted off-targets. A good idea could 
be to test the most promising DPP-IV blocking compounds/ 
GLP-1 agonists in additional well-established animal models 
of PD, in order to verify their exact impact on disease pro-
gression in the context of the complex pathological domains 
activated by this devastating disease. 
DPP-IV inhibition in AD
AD is a chronic neurodegenerative disease characterised by a 
slow and relentless pathological progression and is recognised 
as the cause of 60% to 70% of the total cases of dementia (Mel-
nikova, 2007). The exact causes of AD are not fully established, 
and beside the several attempts to provide a viable explanation 
for the pivotal pathophysiological mechanisms leading to AD, 
the amyloid hypothesis remains the most accredited. But what 
initiates the amyloidogenic cascade? As reported by Heneka 
and collaborators, aberrant immune activation in the brain 
of AD patients might play an important role (Heneka et al., 
2015), despite there is no sufficient evidence to claim whether 
immune activation is the real initiator or it is secondary to 
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tissue damage. Instead, of particular interest have been the 
commonalities found between AD and T2DM. Indeed, both 
pathologies include impaired neuronal insulin signalling and 
endoplasmic reticulum (ER) stress, but also inflammation 
and mitochondrial dysfunction (Vieira et al., 2017). At the 
biochemical level, both T2DM and AD share features like 
amyloid beta (Aβ) aggregation, increased glycogen synthase 
kinase-3 (GSK-3) activity, deregulated protein phosphoryla-
tion, aging-related processes, high cholesterol levels, metabolic 
disorders, blood vessel abnormalities, increased oxidative 
stress, increased inflammatory response, correlation with apo-
lipoprotein E ε4 allele and glyceraldehyde-derived advanced 
glycation end-products, but also impaired neurotrophic sig-
nalling (Ahrén and Hughes, 2005; Li and Hölscher, 2007). In 
regards to the latter point, the naturally-occurring peptide 
PACAP acts as a neurotrophic factor both in the pancreas and 
brain, and has shown partial efficacy both in T2DM and AD 
(Rat et al., 2011; Marzagalli et al., 2015), which unfortunately, 
is strongly limited by DPP-IV proteolytic activity. In addition, 
T2DM is considered a high risk factor for AD (Butterfield et 
al., 2014; Wijesekara et al., 2017). These similarities may justify 
the attempts currently being made to identify a common strat-
egy for intervention for both conditions. Current efforts have 
been focused on tackling DPP-IV in the attempt to improve 
glycaemic control. Unfortunately, the mechanisms underlying 
the neuroprotective effects of DPP-IV inhibitors in AD are not 
entirely clear yet. Nonetheless, as a main target of DPP-IV in-
hibition, the indirect activation and potentiation of the GLP-
1 receptor signalling are thought to be the leading actors in 
DPP-IV driven disease-modifying activities, along with some 
neurotrophic and immune regulatory activities triggered by 
direct enzyme inhibition (Lin and Huang, 2016) (Table 2). 
In human neuronal cells, the DPP-IV inhibitor linagliptin 
has demonstrated to protect neurons against amyloid beta 
(Aβ)-induced cytotoxicity and prevented the activation of 
glycogen synthase kinase 3β (GSK3β) and tau hyperphosphor-
ylation by restoring insulin downstream signalling (disrupted 
in AD). Furthermore, linagliptin alleviated Aβ-induced mito-
chondrial dysfunction and intracellular reactive oxygen spe-
cies (ROS) generation, probably by a mechanism involving the 
activation of 5′ AMP-activated protein kinase (AMPK)-Sirt1 
signalling pathway (Kornelius et al., 2015). In vivo, the efficacy 
of these compounds has been investigated in streptozoto-
cin-induced AD mice models. Researches have highlighted 
how treatment with saxagliptin elevated hippocampal GLP-
1 levels, increased the Aβ and tau protein clearance rate, and 
improved the global neuroinflammatory profile (Kosaraju et 
al., 2013a, b). More recently, the same research group reported 
that linagliptin was effective to increase brain incretin levels 
in a triple transgenic (Tg) animal model of AD (3xTg-AD), 
whilst remarkably dampening amyloid burden, tau phosphor-
ylation, and neuroinflammation (Kosaraju et al., 2017). Inter-
estingly, similar outcomes had already been demonstrated in a 
Tg mouse model of AD administered with sitagliptin, another 
DPP-IV inhibitor with similar efficacy as saxagliptin (Gerrald 
et al., 2012). Chronic administration of sitagliptin in Tg AD 
mice was associated with increased levels of brain GLP-1 and 
dose dependent reductions in inflammatory biomarkers, am-
yloid precursor protein levels and Aβ deposition (D’Amico et 
al., 2010). Interestingly, in a very recent clinical study involv-
ing diabetic patients either diagnosed or not with cognitive 
impairment, administration of sitagliptin increased glycemic 
control and significantly improved cognitive performance (Isik 
et al., 2017). 
A conceivable connection between AD and the ameliora-
tive effects of these compounds (linagliptin, saxagliptin and 
sitagliptin, respectively) seems to be related to their ability to 
rescue the insulin cascade. In fact, as elegantly reported by De 
Felice et al. (2014), insulin resistance is believed to be the main 
pathophysiological link between AD and T2DM. Brain insu-
lin signalling has been reported to decline with age (Cole and 
Frautschy, 2007), the major risk factor for AD, suggesting that 
restoring insulin signalling might be beneficial to patients with 
AD. Of interest is the finding that intranasal insulin adminis-
tration, a preferential route for CNS delivery (Freiherr et al., 
2013), improves memory in healthy adults without affecting 
Table 1 Summary of recent literature addressing the beneficial effects of DPP-IV inhibitors/GLP-1 mimetics in PD
Author Title Drug tested Type of study/model Results 
Svenningsson et al.  
(2016)
Reduced incidence of Parkinson's disease 






case-control study in people with an 
history of DPP-IV inhibitors intake 
↓ Incidence of PD in 




Neuroprotective effects of vildagliptin in 
rat rotenone Parkinson's disease model: 








Liu et al. (2015) Neuroprotective effects of lixisenatide 
and liraglutide in the 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine mouse model 
of Parkinson's disease
Lixisenatide & liraglutide 
(GLP-1 mimetics)
MPTP mouse model of PD ↑ Motor performance
↓ Apoptosis
↑ DA cell survival




Rat rotenone model of PD ↑ Motor performance
↓ Neuroinflammation
↓ Neurodegeneration
Aviles-Olmos et al.  
(2013)




Single-blind clinical trial in patients 
with moderate PD
(NCT01174810)
↑ Motor performance 
↑ Cognitive performance
↓ Body weight (mild)
DPP-IV: Dipeptidyl peptidase IV; GLP-1: glucagon-like peptide-1; PD: Parkinson’s disease; MPTP: methyl-4-phenyl-1,2,3,6-tetrahydropyridine; DA: dopamin; 
RAGE: receptor for advanced glycation end product; NFkappaB: nuclear factor kappaB; Nrf2: nuclear factor (erythroid-derived 2)-like 2.
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circulating levels of insulin or glucose (Benedict et al., 2004; 
Hanson and Frey, 2008). Intranasal insulin also enhances ver-
bal memory in memory-impaired subjects (Dhamoon et al., 
2009) and improves cognitive performance in patients with 
early AD (Craft et al., 2012). All these evidences support the 
employment of new therapies aimed at increasing the insu-
lin pathway in AD. Alternatively, it is conceivable that novel 
therapeutic options for AD will arise from efforts aimed at un-
ravelling mechanisms accounting for brain insulin resistance, 
including the DPP-IV pathway. 
DPP-IV inhibition in MS
MS is a chronic T-cell mediated autoimmune disease that is 
believed to be triggered by a dysfunctional and self-reactive 
immune system, probably determined by genetic vulnerability 
and environmental causes. Unfortunately, the exact aetiology 
still remains largely unknown. MS has for long been regarded 
as a chronic inflammatory disease of the white matter that 
leads to demyelination and eventually to neurodegeneration. 
Pathophysiological features of the disease include the forma-
tion of CNS lesions (referred to as plaques), inflammation 
and destruction of the myelin sheaths surrounding neurons 
(demyelination) (Compston and Coles, 2008). The sequelae 
of symptoms include loss of sensitivity, hypersensitivity or 
numbness, muscle weakness, blurred vision, hyperreflexia, 
muscle spasms, or difficulty in moving; difficulties with coor-
Table 2 Summary of recent literature addressing the beneficial effects of DPP-IV inhibitors/GLP-1 mimetics in AD
Author Title Drug tested Type of study/model Results 
Isik et al. 
(2017)
The effects of sitagliptin, a DPP-4 inhibitor, on 
cognitive functions in elderly diabetic patients with 
or without Alzheimer’s disease
Sitagliptin (DPP-IV 
inhibitor)
Prospective & observational 
human study (205 patients, 52 
with AD)
↑ Cognitive function regardless 
of AD pathology
↓ Need for insulin
Kosaraju et al. 
(2017)
Linagliptin, a dipeptidyl peptidase-4 inhibitor, 
mitigates cognitive deficits and pathology in the 
3xTg-AD mouse model of Alzheimer’s disease
Linagliptin (DPP-
IV inhibitor)





Gejl et al. 
(2016)
In Alzheimer’s disease, 6-month treatment with 
GLP-1 analog prevents decline of brain glucose 












Yang et al. 
(2013)
Subcutaneous administration of liraglutide 
ameliorates Alzheimer-associated tau 
hyperphosphorylation in rats with type 2 diabetes
Liraglutide (GLP-1 
mimetic)




↓ Peripheral insulin resistance
D'Amico et al. 
(2010)










DPP-IV: Dipeptidyl peptidase IV; GLP-1: glucagon-like peptide-1; AD: Alzheimer’s disease; 3xTg-AD: a triple transgenic (Tg) animal model of AD; Aβ: 
amyloid beta.
Table 3 Summary of recent literature addressing the beneficial effects of DPP-IV inhibitors/GLP-1 mimetics in MS
Author Title Drug tested Type of study/model Results 
DellaValle et 
al. (2016)
Glucagon-like peptide-1 analog, liraglutide, 
delays onset of experimental autoimmune 
encephalitis in lewis rats
Liraglutide (GLP-1 
mimetic)




↓ Neuronal cell loss
= astrogliosis
Sun  et al. 
(2016)
Metformin ameliorates the development of 
experimental autoimmune encephalomyelitis by 




EAE model of MS in 
C57BL/6 mice
↑ Treg cell percentage
↓ Th17 cell percentage
↑ Neuroprotective pathways
Preller et al. 
(2007)
TGF-beta1-mediated control of central nervous 
system inflammation and autoimmunity 
through the inhibitory receptor CD26
N/A EAE in DPP-IV-/- mice ↓ T cell immune reactivity to EAE
↑ TGF-β1 production
Reinhold et al. 
(2006)
Dipeptidyl peptidase IV (DP IV, CD26) and 
aminopeptidase N (APN, CD13) as regulators of 
T cell function and targets of immunotherapy in 
CNS inflammation
Combined treatment 
with DPP-IV & 
aminopeptidase N 
inhibitors
In vitro (human peripheral 
blood mononuclear cells and 
isolated T cells) & EAE mice
↑ TGF-β1 secretion
↑ Immunosuppression
↓ Pro-inflammatory cytokine 
release
Reinhold et al. 
(2011)
PETIR-001, a dual inhibitor of dipeptidyl 
peptidase IV (DP IV) and aminopeptidase N 
(APN), ameliorates experimental autoimmune 
encephalomyelitis in SJL/J mice
PETIR-001, a dual DPP-
IV & aminopeptidase N 
inhibitor 
EAE model of MS in SJL/J 
mice 
↓ Clinical signs of MS
↓ Acute phase symptoms
↓ First relapse signs of EAE
Steinbrecher 
et al. (2001)
Targeting dipeptidyl peptidase IV (CD26) 
suppresses autoimmune encephalomyelitis and 




EAE model of MS in 
C57BL/6 mice
↑ TGF-β1 secretion
↓ Proliferation of autoreactive T 
cells
DPP-IV: Dipeptidyl peptidase IV; GLP-1: glucagon-like peptide-1; MS: multiple sclerosis; EAE: experimental autoimmune encephalopathy; TGF-β1: 
transforming growth factor beta 1; N/A: not applicable.
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dination and balance (ataxia); problems with speech or swal-
lowing, visual problems (nystagmus, optic neuritis or double 
vision), fatigue, acute or chronic pain, and bladder and bowel 
difficulties (Pittock and Lucchinetti, 2007). The pathological 
mechanisms seems to be mainly mediated by Th1/Th17 cells, 
where self-reactive effector T cells induce demyelination of 
the brain and spinal cord white matter axons, with subsequent 
neuronal degeneration and cell loss (Table 3).
DPP-IV has attracted major interest as a potential target 
for the development of anti-inflammatory therapies in MS 
based on findings showing the co-localisation of DPP-IV with 
myelin-reactive T cell lines in these patients (Reinhold et al., 
1998, 2008, 2009). A study has suggested that T cells exhibit 
higher levels of DPP-IV/IX compared with peripheral blood 
cells in mice with experimental autoimmune encephalopathy 
(EAE) (Reinhold et al., 2006; Yazbeck et al., 2009). Reinhold 
and co-workers subsequently observed that DPP-IV inhibi-
tors stimulated T-cell clones, inhibited the production of IL-
4, interferon (IFN)-γ and tumour necrosis factor (TNF)-α and 
caused a reduction in pro-inflammatory cytokines produc-
tion in mice with EAE, along with an increase in the levels of 
the immune suppressive transforming growth factor beta 1 
(TGF-β1) and reduced T-cell proliferation. Additional findings 
revealed that the combined inhibition of DPP-IV and amino-
peptidase N (another enzyme exhibiting proteolytic activity) 
activity in vivo could suppress the inflammatory response 
associated with MS. The authors suggested that the achieved 
inhibition on pathogenic T cells could represent a novel and 
efficient remedy to manage the aberrant activation of the in-
nate and adaptive immune system present in autoimmune 
diseases of the CNS, possibly through a mechanism involving 
TGF-β1 (Reinhold et al., 2008). However, the findings about 
TGF-β1 role remain somewhat controversial. In fact, another 
group has demonstrated that in actively induced EAE, there 
is strong expression of TGF-β1 in meningeal and perivascular 
mononuclear infiltrates at the onset of the disease, long lasting 
continued TGF-β1 in mononuclear cells at maximal disease 
severity, and expression in scattered parenchymal cells during 
recovery (Dobolyi et al., 2012). Nevertheless, it is important 
to notice that these data have been gathered from cellular and 
animal models of MS, which may be suitable to study specific 
features of the disease but, at the same time, may lack to repro-
duce with fidelity all of the pathogenic features of the disease. 
Further studies are warranted in order to gain a better under-
standing of the exact mechanisms underlying TGF-β1, which 
will hopefully shed more light into the protective roles of DPP-
IV inhibitors in counteracting MS progression. 
“Berberine” – An Herbal Extract with DPP-IV 
Inhibiting Properties
The implementation of medicinal plants and plant extracts to 
traditional medicine has been practiced for centuries in paral-
lel to modern Western medicine. Among more than 300,000 
seed plants, about 60% have been utilized for therapeutic in-
terventions (Jiao et al., 2011), particularly in South America 
(Cercato et al., 2015), Africa (Olivier et al., 2015), and Asia (Lü 
et al., 2015). More recently, numerous phytochemicals have 
been valued for their ability to improve symptoms triggered 
by chronic metabolic conditions like type 1 and T2DM, as well 
as neurodegenerative diseases. Among these, extracts from 
plants such as Pterocarpus marsupium, Eugenia jambolana, 
Helichrysum stoechas and Rheum palmatum have collectively 
demonstrated positive effects in pathologies of the CNS, which 
were in part associated with their moderate DPP-IV inhibito-
ry activity (Kosaraju et al., 2014; Les et al., 2017; Wang et al., 
2017). However, one extract in particular, known as berberine, 
has revealed robust neuroprotective, anti-apoptotic, anti-in-
flammatory and anti-oxidative properties in various animal 
models of CNS disorders such as AD, PD, stroke, and even 
depression or anxiety (Kulkarni and Dhir, 2008; Ahmed et al., 
2015; Liu et al., 2016; Shen et al., 2016; Maleki et al., 2017). 
Berberine is an isoquinoline alkaloid, present in roots and 
stem-bark of Berberis-species and other plants. It is recognised 
for its insulinotropic effects, but also for its anti-inflammatory 
roles and ability to regulate T cell functions, possibly as a result 
of its potent DPP-IV inhibitory activities (Li and Hölscher, 
2007; Durairajan et al., 2012; Yu et al., 2015; Imenshahidi and 
Hosseinzadeh, 2016; Kharkar, 2016; Liu et al., 2016; Huang et 
al., 2017). The alkaloid mimics the bioactivity of insulin and 
naturally preserves GLP-1 degradation (Singh and Mahajan, 
2013; Kharkar, 2016). Berberis extracts have shown to inhibit 
acetylcholinesterase activity, increase the amyloid precursor 
protein processing towards the non-amyloidogenic pathway 
and increase Aβ clearance in animal and in vitro models of 
AD, hence corroborating the possible therapeutic role in AD 
pathology (Abd El-Wahab et al., 2013; Huang et al., 2017; 
Zhang et al., 2017). Recently, a study has also demonstrated 
that berberine suppresses demyelination and loss of neuro-
physiological function in the EAE model of MS, likely through 
a mechanism involving the sphingosine kinase 1/sphingosine 
1 phosphate pathway (Luo et al., 2017). Interestingly, there 
has been previous evidence indicating that berberine admin-
istration elicited beneficial effects in the EAE model, but these 
were in great part attributed to its ability to preserve blood 
brain barrier integrity (Ma et al., 2010). Additional studies are 
required to clarify the exact mechanism of action exerted by 
berberine in MS and other autoimmune diseases. 
At present, a major hurdle that has strongly limited the use 
of this extract in humans is the poor bioavailability (Liu et al., 
2016). Several studies have shown that human plasma levels 
after oral administration of relatively high doses of berberine 
barely reach the therapeutic window, whilst potentially trig-
gering adverse gastrointestinal effects (Zhang et al., 2008; Hu 
et al., 2012). In the attempt to address the issue, studies inves-
tigating alternative routes of administration through the use of 
spray dried mucoadhesive microparticle formulations (Godu-
gu et al., 2014), delivery using liposomal technology (Liu et al., 
2016) or development of solubility enhancers and permeations 
enhancers are still underway. 
Concluding Remarks
Antidiabetic treatments such as DPP-IV inhibitors or GLP-1 
agonists have shown promise in the treatment of PD, AD, MS 
and cognitive impairment in animals and humans. Notably, 
the study of the pathophysiology of neurodegeneration shared 
between diabetes and certain neurological disorders has given 
rise to a better understanding of disease pathogenesis and has 
opened new treatment possibilities. A common denominator 
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that has been found for these neurological diseases seems to 
be neuroinflammation, which regardless of whether or not 
it represents the initiating event of the pathological cascades 
leading to disease appearance, it represents a viable option for 
the development of therapies.
DPP-IV inhibitors like linagliptin, saxagliptin and sita-
gliptin have been thoroughly investigated in vitro and in 
pre-clinical models of neurological disorders. Whilst more 
investigations are still warranted, these drugs exhibit a good 
safety profile in rodents and produced remarkable improve-
ments through the antioxidant, antiapoptotic, neuropro-
tective, neurorestorative and especially, anti-inflammatory 
mechanisms. As such, DPP-IV inhibitors could be potentially 
introduced as a novel approaches for the management of neu-
rological conditions such as PD, AD and MS, among others. 
Unfortunately, no human clinical trials using DPP-IV in-
hibitors in PD, AD and/or MS have yet been undertaken. One 
of the strongest limitations before stepping forward to human 
studies is the dose regimen used in pre-clinical studies, which 
seems to be 10–20 times higher than the recommended one 
for the treatment of T2DM. As for berberine, most DPP-
IV inhibitors display limited penetration of the blood brain 
barrier (Athauda and Foltynie, 2016), so new strategies are 
warranted before this class of oral hypoglycemic agents can 
be repurposed for the treatment of neurological disorders.
Author contributions: All authors have made substantial intellectual 
contributions to the conception and design of the study as well as literature 
review, analysis, and interpretation. GA performed extensive literature re-
search and drafted the first version of the manuscript. GML and GM contrib-
uted to the literature research and provided important intellectual insights. 
FD provided consultation for the appropriate structuring of the paper and 
helped in reviewing the content. AC conceived the study design, supervised 
the manuscript writing, planning, and editing. All authors contributed to 
data interpretation and manuscript preparation. All authors approved the 
final submitted version.
Conflicts of interest: None declared.
Financial support: None.
Plagiarism check: Checked twice by iThenticate.
Peer review: Externally peer reviewed.
Open access statement: This is an open access article distributed under the 
terms of the Creative Commons Attribution-NonCommercial-ShareAlike 
3.0 License, which allows others to remix, tweak, and build upon the work 
non-commercially, as long as the author is credited and the new creations are 
licensed under identical terms.
Open peer review report:
Reviewer: Manju Bhaskar, National Institute of Neurological Disorders and 
Stroke, USA.
Comments to authors: The paper highlights the significance of DPP-IV in-
hibitors in diabetes and neurological disorders. It gives an insight to the syn-
thetic and natural DPP-IV inhibitors.
 
References
Abd El-Wahab AE, Ghareeb DA, Sarhan EE, Abu-Serie MM, El Demel-
lawy MA (2013) In vitro biological assessment of Berberis vulgaris and 
its active constituent, berberine: antioxidants, anti-acetylcholinesterase, 
anti-diabetic and anticancer effects. BMC Complement Altern Med 
13:218.
Abdelsalam RM, Safar MM (2015) Neuroprotective effects of vildagliptin 
in rat rotenone Parkinson’s disease model: role of RAGE-NFkappaB and 
Nrf2-antioxidant signaling pathways. J Neurochem 133:700-707.
Aertgeerts K, Ye S, Shi L, Prasad SG, Witmer D, Chi E, Sang BC, Wijnands 
RA, Webb DR, Swanson RV (2004) N-linked glycosylation of dipeptidyl 
peptidase IV (CD26): effects on enzyme activity, homodimer formation, 
and adenosine deaminase binding. Protein Sci 13:145-154.
Ahmed T, Gilani AU, Abdollahi M, Daglia M, Nabavi SF, Nabavi SM (2015) 
Berberine and neurodegeneration: A review of literature. Pharmacol Rep 
67:970-979.
Ahrén B, Hughes TE (2005) Inhibition of dipeptidyl peptidase-4 augments 
insulin secretion in response to exogenously administered glucagon-like 
peptide-1, glucose-dependent insulinotropic polypeptide, pituitary ad-
enylate cyclase-activating polypeptide, and gastrin-releasing peptide in 
mice. Endocrinology 146:2055-2059.
An FM, Chen S, Xu Z, Yin L, Wang Y, Liu AR, Yao WB, Gao XD (2015) 
Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau 
phosphorylation against advanced glycation end product-induced neu-
ronal insult: Studies in vivo and in vitro. Neuroscience 300:75-84.
Athauda D, Foltynie T (2016) Insulin resistance and Parkinson’s disease: A 
new target for disease modification? Prog Neurobiol 145-146:98-120.
Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowd-
hury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos 
I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T (2017) 
Exenatide once weekly versus placebo in Parkinson’s disease: a ran-
domised, double-blind, placebo-controlled trial. Lancet 390:1664-1675.
Bae EJ (2016) DPP-4 inhibitors in diabetic complications: role of DPP-4 
beyond glucose control. Arch Pharm Res 39:1114-1128.
Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastro-
enterology 132:2131-2157.
Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W 
(2004) Intranasal insulin improves memory in humans. Psychoneuroen-
docrinology 29:1326-1334.
Brubaker PL, Drucker DJ (2004) Minireview: Glucagon-like peptides reg-
ulate cell proliferation and apoptosis in the pancreas, gut, and central 
nervous system. Endocrinology 145:2653-2659.
Butterfield DA, Di Domenico F, Barone E (2014) Elevated risk of type 2 
diabetes for development of Alzheimer disease: a key role for oxidative 
stress in brain. Biochim Biophys Acta 1842:1693-1706.
Cercato LM, White PA, Nampo FK, Santos MR, Camargo EA (2015) A sys-
tematic review of medicinal plants used for weight loss in Brazil: Is there 
potential for obesity treatment? J Ethnopharmacol 176:286-296.
Cole GM, Frautschy SA (2007) The role of insulin and neurotrophic factor 
signaling in brain aging and Alzheimer’s disease. Exp Gerontol 42:10-21.
Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502-1517.
Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle 
M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton 
B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild 
cognitive impairment: a pilot clinical trial. Arch Neurol 69:29-38.
D’Amico M, Di Filippo C, Marfella R, Abbatecola AM, Ferraraccio F, Rossi 
F, Paolisso G (2010) Long-term inhibition of dipeptidyl peptidase-4 in 
Alzheimer’s prone mice. Exp Gerontol 45:202-207.
Davie CA (2008) A review of Parkinson’s disease. Br Med Bull 86:109-127.
De Felice FG, Lourenco MV, Ferreira ST (2014) How does brain insulin re-
sistance develop in Alzheimer’s disease? Alzheimers Dement 10:S26-32.
DellaValle B, Brix GS, Brock B, Gejl M, Landau AM, Moller A, Rungby J, 
Larsen A (2016) Glucagon-like peptide-1 analog, liraglutide, delays onset of 
experimental autoimmune encephalitis in lewis rats. Front Pharmacol 7:433.
Dhamoon MS, Noble JM, Craft S (2009) Intranasal insulin improves cog-
nition and modulates beta-amyloid in early AD. Neurology 72:292-293; 
author reply 293-294.
Dobolyi A, Vincze C, Pal G, Lovas G (2012) The neuroprotective functions 
of transforming growth factor beta proteins. Int J Mol Sci 13:8219-8258.
Durairajan SS, Liu LF, Lu JH, Chen LL, Yuan Q, Chung SK, Huang L, Li XS, 
Huang JD, Li M (2012) Berberine ameliorates beta-amyloid pathology, 
gliosis, and cognitive impairment in an Alzheimer’s disease transgenic 
mouse model. Neurobiol Aging 33:2903-2919.
During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, 
Klugmann M, Banks WA, Drucker DJ, Haile CN (2003) Glucagon-like 
peptide-1 receptor is involved in learning and neuroprotection. Nat Med 
9:1173-1179.
Fadini GP, Avogaro A (2011) Cardiovascular effects of DPP-4 inhibition: 
beyond GLP-1. Vascul Pharmacol 55:10-16.
Flock G, Baggio LL, Longuet C, Drucker DJ (2007) Incretin receptors for 
glucagon-like peptide 1 and glucose-dependent insulinotropic polypep-
tide are essential for the sustained metabolic actions of vildagliptin in 
mice. Diabetes 56:3006-3013.
Freiherr J, Hallschmid M, Frey WH, 2nd, Brunner YF, Chapman CD, 
Holscher C, Craft S, De Felice FG, Benedict C (2013) Intranasal insulin 
as a treatment for Alzheimer’s disease: a review of basic research and 
clinical evidence. CNS Drugs 27:505-514.
Gejl M, Gjedde A, Egefjord L, Moller A, Hansen SB, Vang K, Rodell A, 
Braendgaard H, Gottrup H, Schacht A, Moller N, Brock B, Rungby J 
(2016) In Alzheimer’s disease, 6-month treatment with GLP-1 analog 
prevents decline of brain glucose metabolism: randomized, placebo-con-
trolled, double-blind clinical trial. Front Aging Neurosci 8:108.
33
Al-Badri G, Leggio GM, Musumeci G, Marzagalli R, Drago F, Castorina A (2018) Tackling dipeptidyl peptidase IV in neurological disorders. 
Neural Regen Res 13(1):26-34. doi:10.4103/1673-5374.224365.
Gerrald KR, Van Scoyoc E, Wines RC, Runge T, Jonas DE (2012) 
Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a sys-
tematic review and meta-analysis. Diabetes Obes Metab 14:481-492.
Godugu C, Patel AR, Doddapaneni R, Somagoni J, Singh M (2014) Ap-
proaches to improve the oral bioavailability and effects of novel antican-
cer drugs berberine and betulinic acid. PLoS One 9:e89919.
Gonçalves A, Marques C, Leal E, Ribeiro CF, Reis F, Ambrósio AF, Fer-
nandes R (2014) Dipeptidyl peptidase-IV inhibition prevents blood-ret-
inal barrier breakdown, inflammation and neuronal cell death in the 
retina of type 1 diabetic rats. Biochim Biophys Acta 1842:1454-1463.
Green BD, Flatt PR, Bailey CJ (2006a) Dipeptidyl peptidase IV (DPP IV) 
inhibitors: A newly emerging drug class for the treatment of type 2 dia-
betes. Diab Vasc Dis Res 3:159-165.
Green BD, Irwin N, Flatt PR (2006b) Pituitary adenylate cyclase-activating 
peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, in-
sulin-releasing activity and antidiabetic potential. Peptides 27:1349-1358.
Gullo F, Ceriani M, D’Aloia A, Wanke E, Constanti A, Costa B, Lecchi 
M (2017) Plant polyphenols and exendin-4 prevent hyperactivity and 
TNF-alpha release in LPS-treated in vitro neuron/astrocyte/microglial 
networks. Front Neurosci 11:500.
Gumuslu E, Mutlu O, Celikyurt IK, Ulak G, Akar F, Erden F, Ertan M (2016) 
Exenatide enhances cognitive performance and upregulates neurotroph-
ic factor gene expression levels in diabetic mice. Fundam Clin Pharmacol 
30:376-384.
Hanson LR, Frey WH, 2nd (2008) Intranasal delivery bypasses the blood-
brain barrier to target therapeutic agents to the central nervous system 
and treat neurodegenerative disease. BMC Neurosci 9 Suppl 3:S5.
Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein 
DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, 
Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Kois-
tinaho J, Latz E, Halle A, Petzold GC, et al. (2015) Neuroinflammation in 
Alzheimer’s disease. Lancet Neurol 14:388-405.
Hjøllund KR, Deacon CF, Holst JJ (2011) Dipeptidyl peptidase-4 inhibition 
increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) 
to a greater extent than peripheral concentrations in anaesthetised pigs. 
Diabetologia 54:2206-2208.
Hu Y, Ehli EA, Kittelsrud J, Ronan PJ, Munger K, Downey T, Bohlen K, 
Callahan L, Munson V, Jahnke M, Marshall LL, Nelson K, Huizenga P, 
Hansen R, Soundy TJ, Davies GE (2012) Lipid-lowering effect of berber-
ine in human subjects and rats. Phytomedicine 19:861-867.
Huang HJ, Chen YH, Liang KC, Jheng YS, Jhao JJ, Su MT, Lee-Chen GJ, 
Hsieh-Li HM (2012) Exendin-4 protected against cognitive dysfunction 
in hyperglycemic mice receiving an intrahippocampal lipopolysaccharide 
injection. PLoS One 7:e39656.
Huang M, Jiang X, Liang Y, Liu Q, Chen S, Guo Y (2017) Berberine im-
proves cognitive impairment by promoting autophagic clearance and 
inhibiting production of beta-amyloid in APP/tau/PS1 mouse model of 
Alzheimer’s disease. Exp Gerontol 91:25-33.
Hunter K, Hölscher C (2012) Drugs developed to treat diabetes, liraglutide 
and lixisenatide, cross the blood brain barrier and enhance neurogenesis. 
BMC Neurosci 13:33.
Imenshahidi M, Hosseinzadeh H (2016) Berberis vulgaris and berberine: an 
update review. Phytother Res 30:1745-1764.
Isik AT, Soysal P, Yay A, Usarel C (2017) The effects of sitagliptin, a DPP-
4 inhibitor, on cognitive functions in elderly diabetic patients with or 
without Alzheimer’s disease. Diabetes Res Clin Pract 123:192-198.
Jalewa J, Sharma MK, Holscher C (2016) Novel incretin analogues improve 
autophagy and protect from mitochondrial stress induced by rotenone in 
SH-SY5Y cells. J Neurochem 139:55-67.
Jiao Y, Wickett NJ, Ayyampalayam S, Chanderbali AS, Landherr L, Ralph 
PE, Tomsho LP, Hu Y, Liang H, Soltis PS, Soltis DE, Clifton SW, Schlar-
baum SE, Schuster SC, Ma H, Leebens-Mack J, dePamphilis CW (2011) 
Ancestral polyploidy in seed plants and angiosperms. Nature 473:97-100.
Jin HY, Liu WJ, Park JH, Baek HS, Park TS (2009) Effect of dipeptidyl 
peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in 
streptozotocin-induced diabetic rats. Arch Med Res 40:536-544.
Kharkar S (2016) Drug Update: Berberine Old Alkaloid with wide spectrum 
of pharmacological activities with new anti - diabetics action. Vidarbha J 
Intern Med 20:46-49.
Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, Joong Lee S, Masliah E, 
Hwang D, Lee HJ, Lee SJ (2013) Neuron-released oligomeric alpha-sy-
nuclein is an endogenous agonist of TLR2 for paracrine activation of 
microglia. Nat Commun 4:1562.
Klein T, Fujii M, Sandel J, Shibazaki Y, Wakamatsu K, Mark M, Yoneyama H 
(2014) Linagliptin alleviates hepatic steatosis and inflammation in a mouse 
model of non-alcoholic steatohepatitis. Med Mol Morphol 47:137-149.
Kornelius E, Lin CL, Chang HH, Li HH, Huang WN, Yang YS, Lu YL, Peng 
CH, Huang CN (2015) DPP-4 inhibitor linagliptin attenuates abeta-in-
duced cytotoxicity through activation of AMPK in neuronal cells. CNS 
Neurosci Ther 21:549-557.
Kosaraju J, Holsinger RMD, Guo L, Tam KY (2017) Linagliptin, a dipep-
tidyl peptidase-4 inhibitor, mitigates cognitive deficits and pathology 
in the 3xTg-AD mouse model of Alzheimer’s disease. Mol Neurobiol 
54:6074-6084.
Kosaraju J, Murthy V, Khatwal RB, Dubala A, Chinni S, Muthureddy Na-
taraj SK, Basavan D (2013a) Vildagliptin: an anti-diabetes agent amelio-
rates cognitive deficits and pathology observed in streptozotocin-induced 
Alzheimer’s disease. J Pharm Pharmacol 65:1773-1784.
Kosaraju J, Madhunapantula SV, Chinni S, Khatwal RB, Dubala A, 
Muthureddy Nataraj SK, Basavan D (2014) Dipeptidyl peptidase-4 inhi-
bition by Pterocarpus marsupium and Eugenia jambolana ameliorates 
streptozotocin induced Alzheimer’s disease. Behav Brain Res 267:55-65.
Kosaraju J, Gali CC, Khatwal RB, Dubala A, Chinni S, Holsinger RM, 
Madhunapantula VS, Muthureddy Nataraj SK, Basavan D (2013b) 
Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin 
induced Alzheimer’s disease. Neuropharmacology 72:291-300.
Kulkarni SK, Dhir A (2008) On the mechanism of antidepressant-like ac-
tion of berberine chloride. Eur J Pharmacol 589:163-172.
Lü S, Wang Q, Li G, Sun S, Guo Y, Kuang H (2015) The treatment of rheu-
matoid arthritis using Chinese medicinal plants: From pharmacology to 
potential molecular mechanisms. J Ethnopharmacol 176:177-206.
Les F, Venditti A, Cásedas G, Frezza C, Guiso M, Sciubba F, Serafini M, 
Bianco A, Valero MS, López V (2017) Everlasting flower (Helichrysum 
stoechas Moench) as a potential source of bioactive molecules with an-
tiproliferative, antioxidant, antidiabetic and neuroprotective properties. 
Ind Crops Prod 108:295-302.
Li L, Hölscher C (2007) Common pathological processes in Alzheimer dis-
ease and type 2 diabetes: a review. Brain Res Rev 56:384-402.
Li L, Liu K, Zhao J, Holscher C, Li GL, Liu YZ (2016) Neuroprotective role 
of (Val(8))GLP-1-Glu-PAL in an in vitro model of Parkinson’s disease. 
Neural Regen Res 11:326-331.
Li Y, Tweedie D, Mattson MP, Holloway HW, Greig NH (2010) Enhancing 
the GLP-1 receptor signaling pathway leads to proliferation and neuro-
protection in human neuroblastoma cells. J Neurochem 113:1621-1631.
Lin CL, Huang CN (2016) The neuroprotective effects of the anti-diabetic 
drug linagliptin against Abeta-induced neurotoxicity. Neural Regen Res 
11:236-237.
Liu CS, Zheng YR, Zhang YF, Long XY (2016) Research progress on berber-
ine with a special focus on its oral bioavailability. Fitoterapia 109:274-282.
Liu W, Jalewa J, Sharma M, Li G, Li L, Holscher C (2015) Neuroprotective 
effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tet-
rahydropyridine mouse model of Parkinson’s disease. Neuroscience 
303:42-50.
Lovshin J, Estall J, Yusta B, Brown TJ, Drucker DJ (2001) Glucagon-like 
peptide (GLP)-2 action in the murine central nervous system is enhanced 
by elimination of GLP-1 receptor signaling. J Biol Chem 276:21489-
21499.
Lovshin JA, Huang Q, Seaberg R, Brubaker PL, Drucker DJ (2004) Extrahy-
pothalamic expression of the glucagon-like peptide-2 receptor is coupled 
to reduction of glutamate-induced cell death in cultured hippocampal 
cells. Endocrinology 145:3495-3506.
Luo J, Chen R, Zeng S, Yu J, Jiang G, Wang L, Qin X (2017) The effects of 
berberine on a murine model of multiple sclerosis and the SPHK1/S1P 
signaling pathway. Biochem Biophys Res Commun 490:927-932.
Ma X, Jiang Y, Wu A, Chen X, Pi R, Liu M, Liu Y (2010) Berberine atten-
uates experimental autoimmune encephalomyelitis in C57 BL/6 mice. 
PLoS One 5:e13489.
Ma Y, Fang S, Zhao S, Wang X, Wang D, Ma M, Luo T, Hong A (2015) A 
recombinant slow-release PACAP-derived peptide alleviates diabetes by 
promoting both insulin secretion and actions. Biomaterials 51:80-90.
Maleki SN, Aboutaleb N, Souri F (2017) Berberine confers neuroprotection 
in coping with focal cerebral ischemia by targeting inflammatory cyto-
kines. J Chem Neuroanat doi: 10.1016/j.jchemneu.2017.04.008.
Marzagalli R, Scuderi S, Drago F, Waschek JA, Castorina A (2015) Emerg-
ing role of PACAP as a new potential therapeutic target in major diabe-
tes complications. Int J Endocrinol 2015:160928.
Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, 
Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, 
Ogawa H (2013) Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves 
endothelial dysfunction in association with its anti-inflammatory effects 
in patients with coronary artery disease and uncontrolled diabetes. Circ J 
77:1337-1344.
34
Al-Badri G, Leggio GM, Musumeci G, Marzagalli R, Drago F, Castorina A (2018) Tackling dipeptidyl peptidase IV in neurological disorders. 
Neural Regen Res 13(1):26-34. doi:10.4103/1673-5374.224365.
Matteucci E, Giampietro O (2009) Dipeptidyl peptidase-4 (CD26): know-
ing the function before inhibiting the enzyme. Curr Med Chem 16:2943-
2951.
Matteucci E, Giampietro O (2015) Mechanisms of neurodegeration in type 
2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 
inhibitors. Curr Med Chem 22:1573-1581.
Melnikova I (2007) Therapies for Alzheimer’s disease. Nat Rev Drug Discov 
6:341-342.
Mentlein R (1999) Dipeptidyl-peptidase IV (CD26)--role in the inactivation 
of regulatory peptides. Regul Pept 85:9-24.
Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hy-
drolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)
amide, peptide histidine methionine and is responsible for their degrada-
tion in human serum. Eur J Biochem 214:829-835.
Nagatsu T (2017) Prolyl oligopeptidase and dipeptidyl peptidase II/dipep-
tidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson’s disease: 
historical overview and future prospects. J Neural Transm (Vienna) 
124:739-744.
Nakamura K, Oe H, Kihara H, Shimada K, Fukuda S, Watanabe K, Takagi T, 
Yunoki K, Miyoshi T, Hirata K, Yoshikawa J, Ito H (2014) DPP-4 inhib-
itor and alpha-glucosidase inhibitor equally improve endothelial func-
tion in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol 
13:110.
Nassar NN, Al-Shorbagy MY, Arab HH, Abdallah DM (2015) Saxagliptin: a 
novel antiparkinsonian approach. Neuropharmacology 89:308-317.
Olivier DK, Van Vuuren SF, Moteetee AN (2015) Annickia affinis and A. 
chlorantha (Enantia chlorantha)--A review of two closely related medici-
nal plants from tropical Africa. J Ethnopharmacol 176:438-462.
Omar B, Ahrén B (2014) Pleiotropic mechanisms for the glucose-lowering 
action of DPP-4 inhibitors. Diabetes 63:2196-2202.
Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, Greig NH (2002) 
A novel neurotrophic property of glucagon-like peptide 1: a promoter of 
nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol 
Exp Ther 300:958-966.
Pittock SJ, Lucchinetti CF (2007) The pathology of MS: new insights and 
potential clinical applications. Neurologist 13:45-56.
Preller V, Gerber A, Wrenger S, Togni M, Marguet D, Tadje J, Lendeckel U, 
Rocken C, Faust J, Neubert K, Schraven B, Martin R, Ansorge S, Brocke 
S, Reinhold D (2007) TGF-beta1-mediated control of central nervous 
system inflammation and autoimmunity through the inhibitory receptor 
CD26. J Immunol 178:4632-4640.
Rat D, Schmitt U, Tippmann F, Dewachter I, Theunis C, Wieczerzak E, 
Postina R, van Leuven F, Fahrenholz F, Kojro E (2011) Neuropeptide 
pituitary adenylate cyclase-activating polypeptide (PACAP) slows down 
Alzheimer’s disease-like pathology in amyloid precursor protein-trans-
genic mice. FASEB J 25:3208-3218.
Reinhold D, Hemmer B, Gran B, Born I, Faust J, Neubert K, McFarland 
HF, Martin R, Ansorge S (1998) Inhibitors of dipeptidyl peptidase IV/
CD26 suppress activation of human MBP-specific CD4+ T cell clones. J 
Neuroimmunol 87:203-209.
Reinhold D, Biton A, Pieper S, Lendeckel U, Faust J, Neubert K, Bank U, 
Tager M, Ansorge S, Brocke S (2006) Dipeptidyl peptidase IV (DP IV, 
CD26) and aminopeptidase N (APN, CD13) as regulators of T cell func-
tion and targets of immunotherapy in CNS inflammation. Int Immuno-
pharmacol 6:1935-1942.
Reinhold D, Bank U, Tager M, Ansorge S, Wrenger S, Thielitz A, Lendeckel 
U, Faust J, Neubert K, Brocke S (2008) DP IV/CD26, APN/CD13 and 
related enzymes as regulators of T cell immunity: implications for exper-
imental encephalomyelitis and multiple sclerosis. Front Biosci 13:2356-
2363.
Reinhold D, Goihl A, Wrenger S, Reinhold A, Kuhlmann UC, Faust J, Neu-
bert K, Thielitz A, Brocke S, Tager M, Ansorge S, Bank U (2009) Role of 
dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activa-
tion: investigations in DP IV/CD26-knockout mice. Clin Chem Lab Med 
47:268-274.
Reinhold D, Bank U, Entz D, Goihl A, Stoye D, Wrenger S, Brocke S, Thiel-
itz A, Stefin S, Nordhoff K, Heimburg A, Tager M, Ansorge S (2011) 
PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and ami-
nopeptidase N (APN), ameliorates experimental autoimmune encepha-
lomyelitis in SJL/J mice. Biol Chem 392:233-237.
Shen JD, Ma LG, Hu CY, Pei YY, Jin SL, Fang XY, Li YC (2016) Berber-
ine up-regulates the BDNF expression in hippocampus and attenuates 
corticosterone-induced depressive-like behavior in mice. Neurosci Lett 
614:77-82.
Shirakawa J, Amo K, Ohminami H, Orime K, Togashi Y, Ito Y, Tajima K, 
Koganei M, Sasaki H, Takeda E, Terauchi Y (2011) Protective effects 
of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased beta cell 
apoptosis induced by dietary sucrose and linoleic acid in mice with dia-
betes. J Biol Chem 286:25467-25476.
Singh IP, Mahajan S (2013) Berberine and its derivatives: a patent review 
(2009 - 2012). Expert Opin Ther Pat 23:215-231.
Steinbrecher A, Reinhold D, Quigley L, Gado A, Tresser N, Izikson L, Born 
I, Faust J, Neubert K, Martin R, Ansorge S, Brocke S (2001) Targeting di-
peptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis 
and up-regulates TGF-beta 1 secretion in vivo. J Immunol 166:2041-
2048.
Sun Y, Tian T, Gao J, Liu X, Hou H, Cao R, Li B, Quan M, Guo L (2016) 
Metformin ameliorates the development of experimental autoimmune 
encephalomyelitis by regulating T helper 17 and regulatory T cells in 
mice. J Neuroimmunol 292:58-67.
Svenningsson P, Wirdefeldt K, Yin L, Fang F, Markaki I, Efendic S, Lud-
vigsson JF (2016) Reduced incidence of Parkinson’s disease after dipepti-
dyl peptidase-4 inhibitors-A nationwide case-control study. Mov Disord 
31:1422-1423.
Trinh J, Farrer M (2013) Advances in the genetics of Parkinson disease. Nat 
Rev Neurol 9:445-454.
Velázquez E, Ruiz-Albusac JM, Blázquez E (2003) Glucagon-like peptide-2 
stimulates the proliferation of cultured rat astrocytes. Eur J Biochem 
270:3001-3009.
Vieira MNN, Lima-Filho RAS, De Felice FG (2017) Connecting Alzheimer’s 
disease to diabetes: Underlying mechanisms and potential therapeutic 
targets. Neuropharmacology doi: 10.1016/j.neuropharm.2017.11.014.
Wang Z, Yang L, Fan H, Wu P, Zhang F, Zhang C, Liu W, Li M (2017) 
Screening of a natural compound library identifies emodin, a natural 
compound from Rheum palmatum Linn that inhibits DPP4. PeerJ 
5:e3283.
Wijesekara N, Gonçalves da Silva RA, De Felice FG, Fraser PE (2017) Im-
paired peripheral glucose homeostasis and Alzheimer’s disease. Neuro-
pharmacology doi: 10.1016/j.neuropharm.2017.11.027.
Yabe D, Eto T, Shiramoto M, Irie S, Murotani K, Seino Y, Kuwata H, 
Kurose T, Seino S, Ahrén B, Seino Y (2017) Effects of DPP-4 inhibitor 
linagliptin and GLP-1 receptor agonist liraglutide on physiological re-
sponse to hypoglycaemia in Japanese subjects with type 2 diabetes: A 
randomized, open-label, 2-arm parallel comparative, exploratory trial. 
Diabetes Obes Metab 19:442-447.
Yada T, Sakurada M, Filipsson K, Kikuchi M, Ahren B (2000) Intraperitoneal 
PACAP administration decreases blood glucose in GK rats, and in normal 
and high fat diet mice. Ann N Y Acad Sci 921:259-263.
Yanagimachi T, Fujita Y, Takeda Y, Honjo J, Sakagami H, Kitsunai H, Ta-
kiyama Y, Abiko A, Makino Y, Kieffer TJ, Haneda M (2017) Dipeptidyl 
peptidase-4 inhibitor treatment induces a greater increase in plasma 
levels of bioactive GIP than GLP-1 in non-diabetic subjects. Molecular 
metabolism 6:226-231.
Yang Y, Zhang J, Ma D, Zhang M, Hu S, Shao S, Gong CX (2013) Subcu-
taneous administration of liraglutide ameliorates Alzheimer-associated 
tau hyperphosphorylation in rats with type 2 diabetes. J Alzheimers Dis 
37:637-648.
Yazbeck R, Howarth GS, Abbott CA (2009) Dipeptidyl peptidase inhibitors, 
an emerging drug class for inflammatory disease? Trends Pharmacol Sci 
30:600-607.
Yu D, Tao BB, Yang YY, Du LS, Yang SS, He XJ, Zhu YW, Yan JK, Yang Q 
(2015) The IDO inhibitor coptisine ameliorates cognitive impairment in 
a mouse model of Alzheimer’s disease. J Alzheimers Dis 43:291-302.
Zhang H, Zhao C, Cao G, Guo L, Zhang S, Liang Y, Qin C, Su P, Li H, 
Zhang W (2017) Berberine modulates amyloid-beta peptide genera-
tion by activating AMP-activated protein kinase. Neuropharmacology 
125:408-417.
Zhang Y, Zhang J, Wang Q, Lei X, Chu Q, Xu GT, Ye W (2011) Intravitreal 
injection of exendin-4 analogue protects retinal cells in early diabetic 
rats. Invest Ophthalmol Vis Sci 52:278-285.
Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, 
Wu P, Ren G, Ning G (2008) Treatment of type 2 diabetes and dyslipid-
emia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 
93:2559-2565.
Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, 
Schmidt K, Bagchi A, Griffin PR, Thornberry NA, Sinha Roy R (2003) 
The role of dipeptidyl peptidase IV in the cleavage of glucagon family 
peptides: in vivo metabolism of pituitary adenylate cyclase activating 
polypeptide-(1-38). J Biol Chem 278:22418-22423.
